Join our team at Zymeworks! We’re looking for a Director of Biostatistics & Programming to drive innovative strategies and support our next generation biotherapeutics pipeline. If you're passionate about making a difference for patients and advancing science, we’d love to connect with you. Apply now and be part of a dynamic, impactful team! #Hiring #BiotechCareers #LifeAtZymeworks
Zymeworks Inc.
Biotechnology Research
Vancouver, BC 27,849 followers
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
About us
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is advancing a robust pipeline of wholly-owned product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibodies. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. Additionally, Zymeworks’ therapeutic platforms have been further leveraged through strategic partnerships.
- Website
-
http://www.zymeworks.com
External link for Zymeworks Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Type
- Public Company
- Founded
- 2003
- Specialties
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Locations
-
Primary
Get directions
114 E 4th Avenue
Suite 800
Vancouver, BC V5T1G4, CA
Employees at Zymeworks Inc.
-
Daniel Dex
Senior Vice President, Corporate Secretary and General Counsel at Zymeworks Inc.
-
Derek Miller
Life sciences executive, board member, consultant and mentor with a successful track record of 25+ years across Corporate Development, Business…
-
Carlos Campoy
Board Director | Retired Public Company CFO | Audit Committee Chair | Global Business Perspective | Strategic Business Partner | Life Sciences Leader…
-
Lindsey Foulkes, PhD
VP Corporate Development
Updates
-
Zymeworks is excited to be at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA, this week! We’re hosting 1-on-1 meetings to discuss our progress in biotherapeutics and explore new opportunities for collaboration. If you’re attending, we’d love to connect—let’s discuss how we can make an impact together. #UBSGlobalHealthcare #Biotech #Innovation #Healthcare
-
-
Join our team at Zymeworks! We’re hiring for multiple roles across Immunology, Drug Safety, Clinical Data, Pathology, and In Vitro Biology. If you’re passionate about advancing science and making a difference for patients, we’d love to hear from you. Apply now and be part of a dynamic, innovative team! https://lnkd.in/gQfH8-Rr #Hiring #BiotechCareers #LifeAtZymeworks
-
-
Today, on Remembrance Day in Canada and Veterans Day in the United States, we honor and remember the courage, sacrifice, and dedication of those who have served and continue to serve. We are deeply grateful for their contributions and the freedoms they have safeguarded. Thank you to all veterans and active-duty members of the armed forces for your unwavering commitment.
-
-
Happy World Science Day! Today, we celebrate the power of science to improve lives and drive innovation. At Zymeworks, we’re committed to advancing scientific discovery and developing biotherapeutics that bring hope to patients with difficult-to-treat diseases. Here's to the researchers, innovators, and visionaries dedicated to a healthier future for all. #WorldScienceDay #Innovation #Biotech #ScienceForGood
-
-
Zymeworks was pleased to participate in the 9th Annual Invest in BC Conference 2024 in Vancouver! Our Vice President of Finance & Strategy, Bijal Desai, shared an overview of Zymeworks and our growing pipeline of wholly-owned novel biotherapeutics. We’re excited to expand our community of supporters as we work to transform patient outcomes through innovation. Thank you to Life Sciences BC for the opportunity to connect! #InvestInBC #Biotech #Innovation #LifeSciences
-
-
Zymeworks is excited to be attending the SITC Annual Meeting in Houston! On November 9, join us as Charles Chen presents his poster on 'Mechanistic QSP Modeling and Translational Strategy for Determining an FIH Dose for ZW171, a Bispecific 2+1 T-Cell Engager Molecule Targeting Mesothelin and CD3.' We look forward to connecting with experts and innovators in cancer immunotherapy. Learn more: https://lnkd.in/gMgBsCG2 #SITC2024 #Immunotherapy #Biotech #Innovation
-
-
Join Zymeworks at PEGS Europe in Barcelona this week! Today, Nina E. Weisser presented on 'Trispecific T Cell Engagers Incorporating Conditional CD28 Co-Stimulation (TriTCE Co-Stim) to Improve Treatment Responses in Oncology.' We’re excited to connect with our peers and discuss the latest advancements in biotherapeutics. #PEGSEurope #Biotech #Innovation #TCellEngagers
-
-
Zymeworks is thrilled to be at PEGS Europe in Barcelona! Today, Thomas Spreter von Kreudenstein presented on 'Azymetric Fc-Based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement.' We look forward to connecting and continuing to share our progress in biotherapeutics. #PEGSEurope #Biotech #Innovation
-
-
We’re pleased to announce that the first patient has been dosed in our Phase 1 clinical trial evaluating our antibody-drug conjugate targeting folate receptor-⍺ expressing advanced solid tumors including ovarian, endometrial, and non-small cell lung (NSCLC) cancers. This milestone highlights our ongoing commitment to bringing innovative therapies to patients with difficult-to-treat cancers and other serious diseases. Learn more about this important trial and how it represents progress in our wholly-owned pipeline: https://lnkd.in/gqqShgGh #ClinicalTrials #Oncology #Innovation
-